

Impact of Statins on Drug-Tolerant Biofilm of Mycobacteria

Aparna gaur¹, K. J. Gohil²

^{1,2}Department of pharmacology, Anand college of pharmacy, Sharda Group of Institutions, Agra-28007, India

Abstract - Tuberculosis is one of the 10 leading reasons for death on the earth. Tuberculosis is an airborne bacterial contamination brought by *M. tuberculosis* which influences any aspect of the body and most normally the lungs. *M. tuberculosis* has waxy covering on its cell surface basically because of the presence of mycolic acid. As of late, a few mycobacterial species, including *M. tuberculosis*, have been found to shape drug-tolerant biofilms in vitro through hereditarily controlled mechanisms. Bacterial biofilms are serious worldwide wellbeing worry because of their capacities to tolerate antibiotics, host defence systems. *M. tuberculosis* needs cholesterol to taint and get by inside the host. Host-directed therapies are a moderately new and promising way to deal with treatment of tuberculosis. Statins are inhibitors of HMG-CoA reductase, a rate-limiting enzyme of the cholesterol biosynthesis pathway, which catalyzes transformation of HMG-CoA reductase into mevalonate and have pleiotropic impacts, including wide reach immunomodulatory, anti-inflammatory, and antimicrobial effects. It has been accounted that cells treated with statins are more resistant to *M. tuberculosis* disease. The point of this review to assemble the accessible logical information on the biofilm development by *Mycobacteria tuberculosis* and impact of statins on *M. tuberculosis* and biofilms of microorganisms.

Index Terms - *Mycobacterium tuberculosis*; cholesterol; statins; biofilms

INTRODUCTION

Tuberculosis (TB) keeps on being a significant wellbeing threat, especially in developing nations. The diseases have been depicted with various names like King's evil, phthisis, tapedic, white plague, Consumption illness, and so forth. It is caused by the bacillus *Mycobacterium tuberculosis* which is spread when individuals who are sick with TB oust microbes into the air, for instance, by coughing, sneezing. It for the most part influences the lungs (pulmonary TB) however can likewise influence different locales

(extrapulmonary TB). There were an estimated 1.2 million TB deaths among HIV (-ve) individuals in 2018, and 251 000 deaths among HIV (+ve) individuals. Geographically, most TB cases in 2018 were in the WHO districts of South-East Asia (44%), Africa (24%) and the Western Pacific (18%), with littler rates in the Eastern Mediterranean (8%), the Americas (3%) and Europe (3%) [1].

Right now, treatment for TB includes utilization of multiple medications specifically isoniazid, rifampicin, pyrazinamide, streptomycin and ethambutol for in any event 6-9 months. Such drawn out treatment results in non-compliance and presence of multi-drug-resistant TB (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Multidrug resistant (MDR) is resistance to at least both isoniazid and rifampicin. Extensive drug resistance (XDR) is resistance to any fluoroquinolone, and in any event one of three second-line injectable medications (capreomycin, kanamycin and amikacin), in addition to multidrug resistance. Resistance from tuberculosis (TB) drugs is a shocking impediment to successful TB care and anticipation all around the world. In 2018, about a large portion of 1,000,000 new instances of rifampicin - resistant TB assessed. TB drug resistance are caused by genetic mutation of the *M. tuberculosis* which renders anti-TB agents ineffective against the mutant tubercle bacilli. It may be emerge because of inappropriate utilization of antibiotics in drug – susceptible TB patients [2].

The cell wall of *M. tuberculosis* contains a tremendous measure of lipids, and a moderately huge part of its genes encode proteins for their synthesis. It has been indicated that mycobacteria aggregate and use cholesterol as a carbon source and for the synthesis of some virulence factors. In mycobacteria, stress, and quorum sensing lead to the development of a biofilm [3].

Biofilm is an unpredictable structure of microbiome having diverse bacterial colonies or single sort of cells in a group; adhere to the surface. These cells are inserted in extracellular polymeric substances, a matrix which is commonly made out of eDNA, proteins and polysaccharides, demonstrated high resistance from antibiotics. Roughly 80% of chronic and recurrent microbial infections in the human body are because of bacterial biofilm. M. tuberculosis can likewise build up a biofilm which assumes a function during the the process of caseous necrosis time spent and cavity development in lung tissue. It was recommended that mycolic acids just as DNA, were crucial in the development and regulation of M. tuberculosis biofilms. Biofilms gives the protection to the microorganism not just from adjusted pH, osmolarity, supplements shortage, mechanical and shear powers yet in addition block the entrance of antibiotics and host's immune cells. In the biofilm structure, microscopic organisms are more resistant to different antimicrobial medicines. along these lines, Drug tolerance by biofilm has been a central point that has impeded effective control and treatment of TB. In a situation where drug resistance is spread quickly. Host-directed treatments are a moderately new and promising way to deal with treatment of tuberculosis [4]. Regulation of explicit host immune pathways, including those that impact inflammation and immunopathology, can restrict mycobacterial infection and pathology, both in cell culture and in animal models.

Statins (3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors) give an intriguing extra avenue to a host-directed therapy, as broadly utilized medications that have demonstrated protected and successful effective. Utilizing host directed therapies as an adjunct to standard anti- TB treatment could likewise reduce the disease span and inevitably lead to decreased relapse rates [5]. These sorts of drugs, including rapamycin, metformin, valproic acid, ibuprofen, and statins, have likewise been appeared to influence the growth of mycobacteria infected cells in vitro investigations [6].

Statins are a class of drugs used to diminish blood cholesterol level. Nonetheless, it was accounted for that Statins have a several impacts beyond their well-known anti-hyperlipidemic action, which incorporate antibacterial, immunomodulatory, anti-oxidative and anticoagulant impacts and so forth; which have been

related with better outcomes in the treatment of a few irresistible ailments. All things considered, the relationship of statins with the multidrug therapy successfully diminishes mycobacterial viability [7]. It was revealed that statins have ability to induce variable degrees of antibacterial activity against S. aureus, B. pumilus, S pneumoniae , M catarrhalis P. aeruginosa , S. Enteric , Acinetobacter, baumannii, proteus mirabilis, Enterobacter cloacae, M. tuberculosis etc.; and various pathogens. Simvastatin, used in the treatment of atherosclerotic cardiovascular disease and hypercholesterolemia, but also has exhibited antibacterial activity in monotherapy against M. tuberculosis [8][9].

Gupta and Kumar (2019) and numerous authors evaluated the MIC estimation of different statin drugs and presumed that Simvastatin, Atorvastatin, and Fluvastatin could be created as likely antimicrobial agents [10]. It was examined simvastatin demonstrated antimicrobial activity against S. Aureus, Pseudomonas aeruginosa, Escherichia coli and Enterococcus faecalis diminishing their biofilm development and viability [40].

Antifungal activity of certain statins against various fungal species has been additionally detailed as simvastatin inhibit planktonic cells and biofilms of Candida and Cryptococcus species. These proof of statins against biofilm make guarantee have an extraordinary potential as a compelling antibacterial tool for biofilms of M. Tuberculosis also. the extent of statin treatment has extended with the emergence of evidence suggesting that due to pleiotropic impacts of statins that are not legitimately connected with their regulation of cholesterol levels, they may end up being valuable for treating various number of diseases include multiple sclerosis (MS), inflammatory bowel diseases (IBDs), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), chronic obstructive pneumonic ailment (COPD), malignant growth, strokes, Parkinson's and Alzheimer's diseases, bacterial infections, and HIV and so forth; [11].

Mycobacterium tuberculosis and pathogenesis:

Mycobacterium tuberculosis is a species of pathogenic microscopic organisms in the family Mycobacteriaceae and the causative agent of Tuberculosis. First found in 1882 by Robert Koch. They are aerobic, non-spore-forming, nonmotile, facultative, bended intracellular rods estimating 0.2-

0.5 μm by 2-4 μm . It has a complex thick waxy cell wall because of its high lipid content; this goes about as an obstruction to anti-microbials and is resistant to lysosomal enzymes, empowering the microorganisms to make due inside macrophages in the body. This waxy layer additionally shields the bacilli from drying out so they may survive many months in the air and dust as long as it is dull. Mycolic acid instigates the aggregation of cholesterol inside peritoneal and alveolar macrophages. Macrophages containing cholesterol and lipid beads look like foamy macrophage derivatives saw in tuberculous granulomas [49].

Fundamentally Infection happens when an individual breathes in droplet nuclei containing tubercle bacilli that arrive at the alveoli of the lungs. There is an almost certain danger of transmission when roughly one to 10 bacilli are scattered through the air. These tubercle bacilli are ingested by alveolar macrophages; most of these bacilli are obliterated or inhibited. A modest number may increase intracellularly and are delivered when the macrophages die [12]. In the event that alive, these bacilli may spread by lymphatic channels or through the bloodstream to more inaccessible tissues and organs (counting lymph nodes, apex of the lung, kidneys, cerebrum, and bone).




Figure no.1 Pathogenesis of *M.tuberculosis*

The alveolar macrophages, after entry of *M. tuberculosis*, produce inflammatory cytokines and chemokines that fill in as a signal for infection. The monocytes, neutrophils, and lymphocytes relocate to the central site of disease, yet they cannot be able to kill the bacteria efficiently. During this time, the bacilli resist the bactericidal mechanisms of the macrophage (phagolysosome) by preventing phagosome-lysosome fusion, duplicate in the phagosome, and cause macrophage necrosis [13].

The association of *M. tuberculosis* ligand with TLRs in the end brings in activation of nuclear transcription factor (NF)- κB and production of proinflammatory cytokines, for example, tumor necrosis factor (TNF)-

α , interleukin (IL)- 1, IL-12, chemokines, and nitric oxide through either myeloid differentiation primary response protein 88 (MyD88)- dependent or MyD88-independent pathway[14][15]. The IFN- γ is the key cytokine for a defensive immune response against *M. tuberculosis*. Humans and mice defective in IFN- γ or IFN- γ receptor genes are more susceptible to *M. tuberculosis* contamination [16].

Drug tolerance by biofilm formation in *M.tuberculosis* Diseases of *M. tuberculosis* are regularly asymptomatic, chronic in a clinically symptomatic state and exceptionally unmanageable to antibiotics [17]. Although molecular mechanisms underlying persistence of the microorganism against the host immune system and chemotherapy remain unclear. Ever-mounting proof shows that the endurance of numerous ecological and pathogenic microbial species against anti-microbials is affected by their capacity to develop as surface-related multicellular communities called biofilms. As of late, a few mycobacterial species, including *M. tuberculosis*, have been found to frame drug-tolerant biofilms in vitro through hereditarily controlled mechanisms [18].

The primary reports originated from cases of tuberculosis disease related with clinical biomaterial, prosthetic joints specifically. Further analyses have demonstrated a decrease in the action of anti-tuberculous medications against tuberculosis biofilms. These revelations offer ascent to enthusiasm for biofilm forming mechanisms as an expected objective for new treatments against tuberculosis. It has been proposed that the significance of biofilms in this infection is because of their cooperation during the process of caseous necrosis and cavitation development in lung tissue, a site where *M. tuberculosis* could form a biofilm [19].

Biofilm development is a significant factor in antimicrobial resistance. It manages numerous bacterial species security against antibiotics ordinarily active against similar microscopic organisms in the planktonic state [20]. Later investigations described *M. tuberculosis* forming "pellicles" in fluid media, with pictures very like what in current times are depicted as biofilms [21]. Coordination inside the biofilm through cell-to-cell communication called quorum sensing (QS) in which aggregation of signaling particles in extracellular climate prompts regulation of the specific genes expression.

Preliminary evidence proposes that biofilms could might be an in vivo way of life of *M. tuberculosis*, adding to their persistence against antibiotics. In an obsessive report by Lenaerts et al., the enduring population of the microorganism after medication treatment of infected guinea pigs was discovered to be in microcolonies of bacteria situated around the acellular edge in the granulomas [22].

Biofilm occupant bacteria show 100-1000 folds higher minimal inhibitory concentration (MIC) when contrasted with planktonic microbes making their treatment a difficult assignment. The ability of Mycobacterium to form biofilms described in 1989. It is accepted that the extracellular polymeric substance (EPS) could go about as an obstruction for antibiotic entrance and along these lines may add to the drug tolerance saw in biofilms. EPS gives mechanical stability to biofilms through physiochemical interactions that include electrostatic powers, hydrogen bonds and van der Waals interactions. In spite of the fact that the composition of EPS changes essentially among various bacterial species, extracellular polysaccharides, proteins, and lipids stay as the key segments of EPS. A number of Mycobacterial species are known to form biofilms including Mycobacterium tuberculosis (Mtb), Mycobacterium smegmatis (Msm), Mycobacterium avium, Mycobacterium marinum and Mycobacterium ulcerans [23]. It has become certain that biofilm-developed cells express properties particular from planktonic cells, one of which is an increase resistance from antimicrobial agents. Notwithstanding, biofilms could shield the pathogenic mycobacterial species from the immune system of the host and could assist bacteria with persist during treatment with antibiotics. A few mycobacteria can build up these structures on surfaces, yet additionally on the in air-media interface [24].

This wonder might be clarified by the diverse composition of the extracellular matrix of the biofilm and the interesting attributes of mycobacterial cell wall, particularly the presence of high lipid levels. As the data accumulated about biofilm formation in mycobacteria it ensures that anti-lipids drug (Statins) have capacity to prevent biofilms. The biofilm development happens through a progression of steps including the initial attachment of the bacterial cells to substratum which is followed by the accumulation of the cells and irreversible authoritative. This

progression is followed by maturation of the biofilm cells which is formed by layering of the aggregates, which after arriving at an extreme thickness begins to scatter just to begin aggregating at a new site.




Figure no.2 Drug resistance in biofilms

Estimated that after changes can happen in biofilm-grown bacteria:

- Induction of the general stress response (a rpoS dependent process in Gram-negative bacteria);
- Increasing expression of multiple drug resistance (MDR) pumps.
- Activating quorum sensing systems; and
- Changing profiles of outer membrane proteins (OMP)

Host directed therapy

Tuberculosis is a significant reason of morbidity and mortality around the world. The current treatment against tuberculosis depends on the organization of a combination of antimicrobials for six months. be that as it may, the lengthy treatment and its adverse impacts favor poor adherence, disappointment, and the development of resistance. In spite of clinical cure, around half of treated patients have permanent lung damage because of abundance inflammation caused by this disease [25].

These realities underscore the need for the advancement of new or potentially improved TB treatment strategies. Host-directed therapies are a generally new and promising way to deal with treatment of tuberculosis. The term HDTs is utilized to characterize treatment choices with small molecules or biologics that can give an antimicrobial or advantageous impact. Modulation of specific host immune pathways, including those that impact inflammation and immunopathology, can restrict mycobacterial infection and pathology, both in cell culture and in animal models. Drugs focusing host processes may generally stay away from the

development of bacterial anti-microbial resistance, a significant general wellbeing worry for tuberculosis. Subsequently, it is fundamental to discover restorative agents with the possibility to shorten treatment time and in the long run, with the ability to fortify the immune response against *M. tuberculosis*.

Host-directed therapy (HDT) is an emerging approach in the field of anti-infectives.

- Host-directed therapy (HDT) is a novel proposal in the field of anti-infectives for overcoming antimicrobial resistance.
- HDT aims to interfere with host cell factors that are required by a pathogen for replication or persistence, to enhance protective immune responses against a pathogen, to reduce intensify inflammation and to balance immune reactivity at sites of pathology.
- In Tuberculosis, HDT aims to enhance the antimicrobial activities of phagocytes through phagosomal maturation, autophagy, and antimicrobial peptides. HDTs also curtail inflammation through involvement with soluble (such as eicosanoids or cytokines) or cellular (co-stimulatory molecules) factors and modulate granulomas to allow the entry of antimicrobials or to restrict tissue damage.
- The goals of HDTs against TB may be several and may include shortening the course of treatment; reducing the number of agents required in combination drug therapy, particularly when toxicity is a concern; improving the efficacy of regimens against drug-resistant TB, which are known to be usually lower than the standard one; preserving lung function in a context of extensive tissue damage.[26]

Here we discussed about repurposed drug as HDT, Repurposing drugs includes finding drug target interactions of established drug treatments, with a aim to utilize them to treat various infections [27]. Repurposing and restoration of the drugs are the new trends/choices to battle these decline circumstances of tuberculosis in the anti-microbials resistance time or in the circumstance of worldwide crisis. Numerous medications have been effectively repurposed to date. In a Nigerian preliminary examination on patients of HIV-MDR-TB coinfection, proficiency of MDR-TB treatment by trimethoprim/sulfamethoxazole TMP/SMX confirmed a significantly shorter time to sputum change in these patients. Sulfadiazine is an anti-leprosy drug which is repurposed in the treatment of MDR-TB and XDR-TB. Suggested that sulfadiazine routine is protected and successful against MDR-TB and TDR-TB treatment. Clofazimine (CZM) is one of the repurposed molecules, has been at first utilized as an anti-leprosy drug since a large portion of the century. It was as of late repurposed for dealing with the treatment of MDRTB. It was accounted for that metformin is a promising candidate as repurposed drug for improving the compelling treatment of tuberculosis.

MET controls the growth of drug-resistant *Mtb* strains, [increases production of mitochondrial reactive oxygen species, and facilitates phagosome-lysosome fusion. In *Mtb*-infected mice, use of MET ameliorated lung pathology, reduced chronic inflammation, and enhanced the specific immune response and the efficacy of conventional TB drugs.

With the worldwide increment in antibiotic resistance from existing antibiotics agents and the quest for new antimicrobial methodologies arriving at a critical stage, there is expanding enthusiasm for the chance of repurposing existing medications that have just been affirmed to treat distinctive clinical conditions however that additionally have antimicrobial activity. Utilizing host-directed therapies as an adjunct to standard anti-TB treatment could likewise diminish the infection duration and in eventually lead to diminished relapse rates [28]. These types of drugs, including rapamycin, metformin, valproic acid, ibuprofen, and statins, have also been shown to affect the growth of mycobacteria in infected cells in in vitro studies. By given their pleiotropic activities, statins are




Figure no.3 Classes of HDT

Statins as repurposed drugs

strong and most potential candidates to be repurposed as novel antimicrobial agents. [29]




Figure no. 4 Mechanism of statins on *M. tuberculosis*

Studies have shown that cholesterol is crucial for the uptake of mycobacteria by macrophages, and it has been found that assemble at the site of *M. tuberculosis* entry.[48] Moreover, cholesterol depletion overcomes the phagosome maturation block experienced by *Mycobacterium tuberculosis* infected macrophages. Statins bring their cholesterol-lowering effect by binding to the active site of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR), a rate-limiting enzyme involved in cholesterol biosynthesis. [30] HMGR is an essential part of the mevalonate pathway, which not only is essential for cholesterol biosynthesis but also contributes to the production of isoprenoids, lipid compounds that are essential for cell signaling and structure. As well as inhibition of cholesterol, statins have also been found to have a number of cholesterol-independent, so called “pleiotropic” effects (anti-inflammatory, anti-bacterial, immunomodulatory, and anti-cancer effects on host cells, and these effects are well characterized).

Pleiotropic effect of statins

Statins inhibit cell proliferation by inhibiting Ras and Rho proteins and stabilizing the levels of cell cycle proteins (p21 and p27). Furthermore, statins induce apoptosis by upregulating proapoptotic proteins (ie, Bax) and downregulating anti apoptotic proteins (ie, Bcl-2). [31] statins induce the phagocytic activity of macrophage J774. It has also been reported that they act as inhibitors of the expression of MHCII induced by IFN- γ in primary endothelial cells, monocytes, and human macrophages, which in turn inhibits the

activation of T lymphocytes. The treatment of mononuclear cells with fluvastatin produced the discrete activation of caspase 1 and moderated the secretion of IL- 1 β , IL-18, and IFN- γ . It has also been demonstrated that statins upregulate IL-10 in the serum of patients with acute coronary syndrome. Another study showed that the in vitro treatment of mononuclear cells with atorvastatin increases the number of NK and NKT cells in peripheral venous blood. It has also been shown that simvastatin therapy in patients with hypercholesterolemia for six months increases the iNKT cells in peripheral venous blood. Other studies show that statins can induce apoptosis in human cells from tumors through the inhibition of Ras signaling pathways. Statins also promote autophagy through the activation of the AMPK-TOR signaling pathway in cells from rhabdomyosarcoma. Treatment with lovastatin increases the expression of Rab7 mRNA by decreasing the synthesis of isoprenyl groups and promoting phagosome maturation. Importantly, statins also impact vascular and immune functions via altered NO signaling leading to improved vascular function, inhibition of leukocyte chemotaxis, and downregulation of leukocyte adhesion and migration at the vascular wall. [32] Emerging reports have indicated the pleiotropic effects (apart from cholesterol-lowering properties) of statin drugs such as inflammation reduction, immunomodulation, and as an anti-bacterial. Recently, various articles have also reported the antimicrobial effects and immunomodulation of statin drugs against *mycobacterium tuberculosis*.

In-vitro and in-vivo effect of statins on *M.tuberculosis* and other Infectious Diseases

The first study to highlight the potential effects of statins on *M. tb* was conducted 20 years ago by Montero et al., where it was observed that fluvastatin modulates the release of type 1 T helper (Th1) and type 2 T helper (Th2) cytokines and consequently activates caspase-1 or leads to the secretion of interleukin (IL)-1 β , IL-18 and interferon gamma (IFN γ).[30] In 2014 Parihar et al. found that mononuclear cells and monocyte-derived macrophages from patients with familial hypercholesterolemia who had received statin therapy for at least six months were more resistant to infection with *M. tuberculosis*. In the same study, bovine bone marrow-derived macrophages (BMDMs) were treated with 50 μ M of simvastatin and were

infected with *M. TB* for four hours at 37 °C. The results depicted a significant decrease in bacterial growth without alterations in cellular viability. Metabolic rescue experiments demonstrated that statins reduce membrane cholesterol levels, particularly by the mevalonate-isoprenoid arm of the sterol pathway. This promoted phagosomal maturation (EEA-1/Lamp-3) and autophagy (LC3-II), as shown by confocal microscopy and Western blot in macrophages. [8]

Guerra-De-Blas et al. analyzed the effects of simvastatin on the treatment of *M.tb* infection. Observed that simvastatin decreased the growth of *M. tuberculosis* in PBMCs, increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, promoted the secretion of the cytokines IL-1 β and IL-12p70, and activated apoptosis and autophagy in monocytes, resulting in a significant depletion in bacterial load. Also observed an increase in IL-10 production. simvastatin activates several immune mechanisms that favor the containment of *M. tuberculosis* infection, which providing relevant evidence to consider statins as candidates for host-directed therapy.[33]

Recently, Gupta and Kumar (2019) have reviewed the MIC value of various statin drugs and concluded that Simvastatin, Atorvastatin, and Fluvastatin could be developed as potential antimicrobial agents.[10] Lobato et al. investigated that statin increase rifampin mycobactericidal activity for *M. tuberculosis*, both statins (2 μ M atorvastatin and 2 μ M simvastatin) reduced the viability of the mycobacteria by approximately 75% and also showed an additive effect with rifampicin (1 μ g/mL rifampicin plus 0.2 μ M atorvastatin or 0.2 μ M simvastatin). However, for *M. leprae* strain, they inoculated 1 \times 10⁴ live *M. leprae* strains into plantar pads of each shepherd model of BALB/c mice and noticed that only atorvastatin showed an additional effect with RIF. [34]

Dutta et al. (2016) confirmed that simvastatin therapy as an adjuvant to standard treatment reduced the time to obtain a negative culture in BALB/c mice infected with *M. tuberculosis* H37Rv by aerosols. They also evaluated the relapse rates in mice treated with simvastatin (60 mg/kg) for 2.5, 3.5, and 4.5 months. Relapse was evaluated three months after stopping treatment. The results showed that treatment with anti-TB drugs plus simvastatin reduced the percentage of

relapses by 50% compared with treatment with only anti-TB drugs.[7]

Dutta et al. conducted another study in 2019 on female C3HeB/FeJ mice, in which Pravastatin (7.8 μ M), simvastatin (0.2 μ M) and fluvastatin (0.032 μ M) enhanced the activity of first-line anti-TB drugs (0.006 μ M INH plus 0.0055 μ M RIF and 81.23 μ M PZA). However, atorvastatin and mevastatin showed no effect on mycobacterial growth at non-toxic doses. Among all statins, pravastatin exhibited the most potent adjunctive activity with the least toxicity by modulating phagosomal maturation characteristics in THP-1 macrophages. [50]

Skerry et al. simvastatin reduces bacterial load in an in vitro macrophage model and enhances the effects of standard treatment in chronically infected BALB/c mice. standard oral regimen of rifampicin (10 mg/kg), isoniazid (10 mg/kg) and pyrazinamide (150 mg/kg) given five times weekly, the addition of 25 mg/kg simvastatin enhanced bacillary killing, reducing the number of lung cfu by an additional 1 log₁₀ at Day 28 (P < 0.01) and by a further 1.25 log₁₀ at Day 56 (P < 0.01).[9] Pravastatin modulated phagosomal maturation characteristics in macrophages, phenocopying macrophage activation, and exhibited potent adjunctive activity in the standard mouse model of TB chemotherapy and in a mouse model of human-like necrotic TB lung granulomas.[35] Several retrospective cohorts and population-based case-control studies have also highlighted the effects of statin on the risk of developing TB. [52][53]

Other than this Simvastatin showed a significant antimicrobial effect against Methicillin-sensitive staphylococcus aureus (MSSA) MIC 29.2 mg/L and to a lesser extent against methicillin-resistant staphylococcus aureus (MRSA) MIC 74.9 mg/L.[36] [37] The MIC-value for simvastatin against *S pneumoniae* and *M catarrhalis* was determined 15 mg/mL (36 mmol/L).[39] Statins also induce tumor-specific apoptosis through mitochondrial apoptotic signaling pathways, which are activated by the suppression of mevalonate or geranylgeranyl pyrophosphate (GGPP) biosynthesis and It has been observed that lovastatin interferes with the replication of hepatitis C virus RNA through the inhibition of geranylgeranylation protein of the host. Statins also inhibit the assembly of dengue virus virions through a mechanism independent of cholesterol levels. It has also shown antiviral effects on cytomegalovirus, the

Epstein-Barr virus and HIV infection.[38] Bergman et al. found a MIC value of 15.6 µg/mL for simvastatin against *Streptococcus pneumoniae*. [39] Ribeiro et al., 2017 In vivo, atorvastatin plus fluconazole increased the survival of mice and reduced the burden of *C. gattii* in the lungs and brain. Authors demonstrated the in vivo efficacy of topical Simvastatin against microbial infection in BALB/c mice [47]

These studies have demonstrated that cholesterol plays a carping role in the pathogenesis of *M. tuberculosis* infections and other infectious diseases in several ways, including the entrance of *M. tuberculosis* into host macrophages, phagosome formation, the arrest of phagosomal maturation in *M. tuberculosis*-containing phagosomes, and the energy utilisation of intracellular *M. tuberculosis*. Statins can stop TB infection by reducing macrophage cholesterol and phagocytosis. Statin can also reduce cholesterol levels within phagosomal membranes and counteract the *M. tuberculosis* induced inhibition of phagosomal maturation to further host-induced autophagy in human macrophages and experimental mouse models. Thus, statins might exert a protective effect against TB infection.

Anti-biofilm effects of statin

Graziano et al. 2015 Simvastatin has shown pronounced antimicrobial activity against *S. aureus* biofilms by reducing their formation and viability. Simvastatin's MIC was evaluated 15.65 µg/mL for *S. aureus* 29213 and 31.25 µg/mL for the other strains of *S. aureus*. [40] In established biofilm simvastatin decreased *P. gingivalis* counts by up to more than 1'000-fold [41]. In vitro studies show that non candidacidal concentrations of simvastatin (1, 2.5, or 5 µM) inhibit biofilm production in vitro by laboratory and clinical isolates of *C. albicans* in both microscopic and spectrophotometric assays. [42]

In other study, Simvastatin showed inhibitory effect against *Candida* spp. and *Cryptococcus* spp with MIC values ranging from 15.6 to 1000 mg L⁻¹ and from 62.5 to 1000 mg L⁻¹, respectively. The combination of simvastatin with itraconazole and fluconazole showed synergism against *Candida* spp. and *Cryptococcus* spp., while the combination of simvastatin with amphotericin B was synergistic only against *Cryptococcus* spp. Concerning the biofilm assays, simvastatin was able to inhibit both growing biofilm and mature biofilm of *Candida* spp. and *Cryptococcus*

spp.[43] Statins also inhibit the formation of biofilms of *Candida albicans* [44] and, in *C. glabrata*, reduce ergosterol levels, inhibit their growth, and cause the loss of mtDNA. [45][46] These studies show that statins slow the growth of some microorganisms, including some resistant bacteria, and also show that they can interfere with biofilm formation.

CONCLUSION

Emergence and spreading of antibiotics resistant *M. tuberculosis* due to biofilm formation have worsened the current situation across the globe. In this review we have discussed about pathogenesis of *M. tuberculosis*, drug tolerance by biofilm formation and statins provided protective effects against *M. tuberculosis* through immunomodulation and anti-microbial activity. the most convincing evidence is statins showed anti- biofilm action towards various gram-positive and gram-negative bacteria and on some viruses and fungi. These effects have clinical relevance because within the biofilm, bacteria are protected against the action of antibodies, the attack of phagocytic cells, and the effect of antimicrobials. Therefore, it is very important to note that statins have the potential to inhibit the growth of resistant bacteria and interfere with the biofilm formation process. It is believed that the extracellular polymeric substance (EPS) could act as a barrier for antibiotic penetration in biofilm. The Extracellular matrix of *M. tuberculosis* Biofilm contains the high amount of lipids; therefore, statin have ability to prevent this barrier. Such multidisciplinary communication can hope that prevention and inhibition of biofilms of *M. tuberculosis* can be achieved through use of statins in near future which might be help to achieve the goal of TB free world declared by WHO.

REFERENCES

- [1] World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019.
- [2] Agyeman AA, Ofori-Asenso R. Tuberculosis— an overview. *J Public Health Emerg* 2017; 1:7.
- [3] Chen, J. M., G. J. German, D. C. Alexander, H. Ren, T. Tan & J. Liu, (2006) Roles of Lsr2 in colony morphology and biofilm formation of

- Mycobacterium smegmatis*. *J Bacteriol* 188: 633-641.
- [4] Kolloli A and Subbian S (2017) Host-Directed Therapeutic Strategies for Tuberculosis. *Front. Med.* 4:171. doi: 10.3389/fmed.2017.00171
- [5] Machelart A, Song OR, Hoffmann E, Brodin P. Host-directed therapies offer novel opportunities for the fight against tuberculosis. *Drug Discov Today.* 2017; 22(8):1250–1257. doi:10.1016/j.drudis.2017.05.005
- [6] Zumla, J. Chakaya, M. Hoelscher, F. Ntoumi, R. Rustomjee, C. Vilaplana, et al. Towards host-directed therapies for tuberculosis *Nat Rev Drug Discov*, 14 (2015), pp. 511-512
- [7] N. K. Dutta, N. Bruiners, M. L. Pinn et al., “Statin adjunctive therapy shortens the duration of TB treatment in mice,” *The Journal of Antimicrobial Chemotherapy*, vol. 71, no. 6, pp. 1570–1577, 2016.
- [8] Parihar, S. P., Guler, R., Khutlang, R., Lang, D. M., Hurdayal, R., Mhlanga, M. M., et al. (2014). Statin therapy reduces the *Mycobacterium tuberculosis* burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. *J. Infect. Dis.* 209, 754–763. doi: 10.1093/infdis/jit550
- [9] Skerry, C., Pinn, M. L., Bruiners, N., Pine, R., Gennaro, M. L., and Karakousis, P. C. (2014). Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. *J. Antimicrob. Chemother.* 69, 2453–2457. doi: 10.1093/jac/dku166
- [10] Gupta M, Kumar A (2019) Comparison of minimum inhibitory concentration (MIC) value of statin drugs: a systematic review. *Anti-Infect Agents.*
- [11] Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med* 2015;7:51.
- [12] CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection— United States, 2010. *MMWR* 2010; 59 (No. RR-05). www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e
- [13] E.-K. Jo, C.-S. Yang, C. H. Choi, and C. V. Harding, “Intracellular signalling cascades regulating innate immune responses to mycobacteria: branching out from Toll-like receptors,” *Cellular Microbiology*, vol. 9, no. 5, pp. 1087–1098, 2007.
- [14] M. Yamamoto, S. Sato, H. Hemmi et al., “Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway,” *Science*, vol. 301, no. 5633, pp. 640–643, 2003.
- [15] J. Chan and J. Flynn, “The immunological aspects of latency in tuberculosis,” *Clinical Immunology*, vol. 110, no. 1, pp. 2–12, 2004.
- [16] A. M. Cooper, “Cell-mediated immune responses in tuberculosis,” *Annual Review of Immunology*, vol. 27, pp. 393–422, 2009.
- [17] *Expert Rev Anti Infect Ther.* 2012 September; 10(9): 1055–1066. doi:10.1586/eri.12.88.
- [18] Esteban J and García-Coca M (2018) *Mycobacterium Biofilms*. *Front. Microbiol.* 8:2651. doi: 10.3389/fmicb.2017.0265
- [19] Basaraba RJ, Ojha AK (2017). *Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions*. *Microbiol Spectr* 5(3). doi: 10.1128/microbiolspec.TB2-0024-2016
- [20] Ciofu O, Rojo-Moliner E, Macià MD, Oliver A. Antibiotic treatment of biofilm infections. *APMIS.* 2017;125(4):304–319. doi:10.1111/apm.12673
- [21] Solano C, Echeverz M, Lasa I. Biofilm dispersion and quorum sensing. *Curr Opin Microbiol.* 2014;18:96–104.
- [22] Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. *Antimicrob Agents Chemother.* 2007; 51(9):3338–3345. Pathological evidence for the presence of drug-tolerant persisters of *Mycobacterium tuberculosis* in multicellular microcolonies. [PubMed: 17517834]
- [23] Schulze-Robbecke R, Fischeder R (1989). *Mycobacteria in biofilms*. *Zentralbl Hyg Umweltmed* 188(3-4): 385-390. PMID: 2667558
- [24] Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, Alahari A, Kremer L, Jacobs WR, Jr., Hatfull GF (2008). Growth of *Mycobacterium tuberculosis* biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. *Mol Microbiol* 69(1): 164-174. doi: 10.1111/j.1365-2958.2008.06274.x

- [25] Castelnuovo B. 2010. A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa. *Afr Health Sci* 10: 320–324.
- [26] Sachan M, Srivastava A, Ranjan R, Gupta A, Pandya S, Misra A, et al. Opportunities and challenges for host-directed therapies in tuberculosis. *Curr Pharm Des* 2016; 22: 2599-604.
- [27] Miró-Canturri A, Ayerbe-Algaba R and Smani Y (2019) Drug Repurposing for the Treatment of Bacterial and Fungal Infections. *Front. Microbiol.* 10:41. doi: 10.3389/fmicb.2019.00041
- [28] Chow SC. 2009. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. *Arch Immunol Ther Exp (Warsz)* 57:243–251. doi:10.1007/s00005-009-0038-5
- [29] Welsh A-M, Kruger P, Faoagali J. 2009. Antimicrobial action of atorvastatin and rosuvastatin. *Pathology* 41:689–691. doi:10.3109/0031302090 3305860.
- [30] Sirtori CR. The pharmacology of statins. *Pharmacol Res.* (2014) 88:3–11. doi: 10.1016/j.phrs.2014.03.002
- [31] Czabotar, P.E.; Lessene, G.; Strasser, A.; Adams, J.M. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 49–63. [CrossRef] [PubMed]
- [32] Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. *Nat Rev Immunol.* 2006;6(5): 358–370.
- [33] Guerra-De-Blas PDC, Bobadilla-Del-Valle M, Sada-Ovalle I, Estrada-García I, Torres-González P, López-Saavedra A, Guzmán-Beltrán S, Ponce-de-León A and Sifuentes-Osornio J (2019) Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis. *Front. Microbiol.* 10:2097. doi: 10.3389/fmicb.2019.02097
- [34] L. S. Lobato, P. S. Rosa, J. S. Ferreira et al., “Statins increase rifampin mycobactericidal effect,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 10, pp. 5766–5774, 2014.
- [35] Del Real, G., Jiménez-Baranda, S., Mira, E., Lacalle, R. A., Lucas, P., Gómez-Moutón, C., Mañes, S. (2004). Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity. *The Journal of Experimental Medicine*, 200(4), 541–547.
- [36] S. Jerwood, J. Cohen, Unexpected antimicrobial effect of statins, *Journal of Antimicrobial Chemotherapy*, Volume 61, Issue 2, February 2008, Pages 362–364, <https://doi.org/10.1093/jac/dkm496>
- [37] Masadeh et al.: Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin. *Annals of Clinical Microbiology and Antimicrobials* 2012 11:13.
- [38] Beckwitt, C.H., Brufsky, A., Oltvai, Z.N. et al. Statin drugs to reduce breast cancer recurrence and mortality. *Breast Cancer Res* 20, 144 (2018). <https://doi.org/10.1186/s13058-018-1066-z>
- [39] Bergman P, Linde C, Putsep K, Pohanka A, Normark S, Henriques-Normark B, et al. Studies on the antibacterial effects of statins—in vitro and in vivo. *PloS one.* 2011; 6(8): e24394. doi: 10.1371/journal.pone.0024394 PubMed PMID: PMID: 21912631; PubMed Central PMCID: PMC3166163.
- [40] Graziano TS, Cuzzullin MC, Franco GC, Schwartz-Filho HO, de Andrade ED, Groppo FC, et al. (2015) Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm. *PLoS ONE* 10(5): e0128098. doi: 10.1371/journal.pone.0128098
- [41] Marta Kamińska, Ardita Aliko, Annelie Hellvard, Agata Marczyk & Piotr Mydel (2017) Effects of statins on multispecies oral biofilm, *Journal of Oral Microbiology*, 9:sup1, 1325249, DOI: 10.1080/20002297.2017.1325249
- [42] Liu, G., Vellucci, V., Kyc, S. et al. Simvastatin Inhibits Candida albicans Biofilm In Vitro. *PediatrRes* 66, 600–604(2009). <https://doi.org/10.1203/PDR.0b013e3181bd5bf8>
- [43] Talita SignoretiGraziano, Maria Claudia Cuzzullin1, Gilson Cesar Franco2, Humberto Osvaldo Schwartz-Filho, Eduardo Dias de Andrade, Francisco Carlos Groppo, Karina Cogo-Müller, 2015, Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm, *Plos one*
- [44] G. Liu, V. F. Vellucci, S. Kyc, and M. K. Hostetter, “Simvastatin inhibits Candida albicans biofilm in vitro,” *Pediatric Research*, vol. 66, no. 6, pp. 600–604, 2009.

- [45] C. Westermeyer and I. G. Macreadie, "Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in *Candida glabrata*," *FEMS Yeast Research*, vol. 7, no. 3, pp. 436–441, 2007.
- [46] S. K. Natesan, P. H. Chandrasekar, G. J. Alangaden, and E. K. Manavathu, "Fluvastatin potentiates the activity of caspofungin against *Aspergillus fumigatus* in vitro," *Diagnostic Microbiology and Infectious Disease*, vol. 60, no. 4, pp. 369–373, 2008.
- [47] Thangamani, S., Mohammad, H., Abushahba, M. F. N., Hamed, M. I., Sobreira, T. J. P., Hedrick, V. E., et al. (2015a). Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. *Sci. Rep.* 5:16407. doi: 10.1038/srep16407
- [48] Gatfield, J., and J. Pieters. 2000. Essential role for cholesterol in entry of mycobacteria into macrophages. *Science* 2:1647-1650.
- [49] Korf J, Stoltz A, Verschoor J, De Baetselier P, Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. *Eur J Immunol.* 2005;35(3):890-900.
- [50] Montero MT, Hernández O, Suárez Y, et al.: Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. *Atherosclerosis.* 2000, 153:303-313. 10.1016/s0021-9150(00)00417-2
- [51] Dutta NK, Bruiners N, Zimmerman MD, Tan S, Dartois V, Gennaro ML, Karakousis PC: Adjunctive host-directed therapy with statins improves tuberculosis-related outcomes in mice. *J Infect Dis.* 2019, pii:jiz517. 10.1093/infdis/jiz517
- [52] Kang YA, Choi NK, Seong JM, et al.: The effects of statin use on the development of tuberculosis among patients with diabetes mellitus. *Int J Tuberc Lung Dis.* 2014, 18:717-724. 10.5588/ijtld.13.085
- [53] Lee MY, Lin KD, Hsu WH, Chang HL, Yang YH, Hsiao PJ, Shin SJ: Statin, calcium channel blocker and Beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetes. *Int J Mol Sci.* 2015, 16:11369-11384 10.3390 /ijms 160511369